Fizikalni mehanizmi i metode u tumorskim terapijama i prijenosu lijekova do tumora by ERIM BEŠIĆ
Despite the existence of many modes of therapy that have proved their efficacy, such
as chemotherapy, immunotherapy, radiotherapy, thermotherapy or gene therapy, succes-
sful treatment of cancer still remains a challenge. Development of new anticancer drugs
has not been very successful since it has been found that the administration of drugs
alone does not result in their high tumor concentrations and reduction in systemic toxi-
city. The main hindrances to the distribution of anticancer agents to the tumor site are
the highly disorganized tumor vasculature, high blood viscosity in the tumor and high
interstitial pressure within the tumor tissue (1–3). In the attempt to improve the anti-
cancer therapy, various delivery systems have been introduced to minimize the systemic
drug exposure and bring the anticancer drugs to the site of interest – among them, poly-
mer-drug conjugates (4–6), liposomes (7), polymeric micelles (8, 9), micelles (10), micro-
particles (11), nanoparticles (12–15), lipid nanoparticles (16, 17) and implants (18).
Blood vessels in tumors greatly differ from the blood vessels in normal tissues, show-
ing abnormal vascular architectures and deficient lymphatic drainage systems (19). It
was found that these abnormalities are responsible for enhanced vascular permeability
for macromolecules, which are retained in tumors for extended periods (20). This phe-
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nomenon, named enhanced permeability and retention effect, is the hallmark of solid tu-
mor vasculature and represents a key mechanism for solid tumor targeting (21, 22).
Apart from the enhanced permeability and retention effect, another strategy em-
ployed to enhance the tumor delivery of anticancer agents is local chemotherapy, which
has been recognized as a potential method for delivering high drug doses to the target
sites, while minimizing systemic exposure (23). In this type of delivery, drug delivery
systems are administered at the local site of the tumor and facilitate more effective expo-
sure of cancer cells to drugs and hence greater antitumor activity (24).
In addition to enhanced permeability and retention effect and local chemotherapy,
some special strategies, such as receptor-mediated drug delivery, have been adopted for
enhancing the tumor delivery of anticancer agents. Here, the targeting is generally achi-
eved by the mechanism of folate-receptor-mediated endocytosis using folate-conjugated
polymeric micelles (25), folate-conjugated polymers (26) and folate-coated solid lipid na-
noparticles (27).
The measured pH values of the majority of solid tumors are in the range of 5.7–7.8,
which is much lower than the pH values of the surrounding normal tissues (28). This
difference in extracellular pH between tumor and normal tissues established a new spe-
cial strategy for drug delivery named pH-sensitive anticancer drug delivery. Han et al.
(29) introduced a new pH-sensitive functional group containing water-soluble polymers,
modified with sulfonamide self-assembled nanoparticles. Drug transport using such pH-
-sensitive drug carriers enhances drug release and interaction with cells at tumor pH (30).
Also, pH-sensitive polymers showed enhanced cytoplasmic delivery of many therapeu-
tics (31, 32), which is a major advantage compared to other drug delivery systems.
As it can be seen, extensive research performed in the area of drug delivery to tu-
mors based on the principles of biology and chemistry resulted in discovery and devel-
opment of new drug strategies employing different drug carriers. Although all of these
chemical and biochemical strategies have resulted in successful enhancement of drug
concentrations at tumor sites and marked anticancer activities, they have not shown any
appreciable progress in anticancer therapies and only very few products have actually
reached the market. In order to introduce new mechanisms of drug delivery and to de-
velop suitable carrier systems for anticancer agents, new strategies based on application
of physical methods and techniques have been established in the last two decades. This
paper reviews the mechanistics of these novel strategies with examples of recently re-
ported experimental studies, where these approaches have been successfully implemented.
APPLICATION OF ULTRASOUND IN DRUG DELIVERY TO TUMORS
Encapsulation of the drug into Pluronic micelles
During the last two decades, the drug carriers encapsulated into polymeric micelles,
a transport system that offers numerous advantages, have been a constant focus of sci-
entific interest (33, 34). Firstly, micelles are self-assembled spherical nanoparticles that
have the appropriate size to avoid renal excretion and at the same time allow extrava-
sation through leaky blood vessels. This results in gradual accumulation of the micellar-
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-encapsuled drug in the interstitial space between the tumor cells, which enables passive
tumor targeting via enhanced permeability and the retention effect. In addition, this drug
delivery system is independent of drug character and also provides longer circulation
time in the blood (35). Furthermore, incorporation of the drug into micelles is relatively
simple compared to covalent binding of the drug to the polymeric carrier (36).
Polymeric micelles are hydrophobic-hydrophilic block polymers, with the hydrophilic
blocks comprising poly(ethylene oxide) (PEO) chains. The dynamic PEO chains prevent
particle opsonization and render them unrecognizable by the reticulo-endothelial sys-
tem (37). This characteristic of PEO chains has promoted development of new techni-
ques for encapsulation of particles (drugs) based on the processes of physical adsorption
and chemical conjugation.
The most frequently used copolymer for encapsulation of drugs into micelles is tri-
block PEO-PPO-PEO Pluronic copolymer [PPO stands for poly(propylene oxide)]. PPO
blocks form the core, whereas flanking PEO blocks form the shell (corona) of the micelle
(38). The phase state of Pluronic micelles can be controlled using both the variable PPO/PEO
block length ratio and concentration (39). The hydrodynamic radii of Pluronic micelles
at physiological temperatures range between 10 and 20 nm, which makes them highly
suitable for potential drug carriers.
Drug release and uptake mediated by ultrasound
Encapsulation of a drug into micelles decreases systemic concentration of the free
drug, which diminishes intracellular drug uptake by normal cells and reduces unwanted
side effects caused by drug interaction with healthy tissues. However, encapsulation of
the drug into micelles also decreases its uptake by cancerous cells (40, 41). To overcome
this problem, it was necessary to find a mechanism that, at the appropriate time, triggers
the release of the drug from the sequestering container at the tumor site. Recently, it was
shown that such a controlled triggering mechanism could be achieved by the applica-
tion of focused ultrasound (42, 43). Ultrasound induces formation of cavitation regions
in the cell membrane, which results in increased membrane permeability. This process,
called sonoporation, is responsible for enhanced intracellular uptake of both the released
and micellar-encapsulated drug (44, 45). Therefore, focusing ultrasound on the tumor
provides three important advantages: (i) ultrasound increases the permeability of blood
vessels (46), thus increasing micelle extravasation at the tumor site; (ii) sonication (irra-
diation by ultrasound) enhances drug release from micelles, and subsequently increases
the concentration of the free (non-encapsulated) drug at the tumor site; (iii) ultrasound-
mediated pertubation of cell membrane and other cellular structures results in forma-
tion of cavities along the cell membrane (sonoporation), thereby increasing the uptake of
micellar-encapsulated drugs. All three factors work in synergy to ensure localized and
effective drug uptake at the tumor site.
Although the exact mechanism of sonoporation is still not fully understood, the trig-
gering mechanism that releases the drug from micelles is analogous to the common ef-
fect of acoustic cavitation, frequently used in many biomedical applications (e.g. for ul-
trasonic sterilization of the laboratory and medical equipment) (47). Acoustic cavitation
refers to the formation, growth by »rectified diffusion« and collapse of gas- and vapor-
filled bubbles in liquids exposed to ultrasound above threshold intensity (48). This pro-
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cess is based on conversion of the low energy density of the ultrasound field into the
high energy density in the interior and the surroundings of the bubbles. Such accumula-
tion of ultrasonic energy induces tremendous internal pressures and temperatures within
these small bubbles, which tend to rise until they violently collapse.
Husseini et al. (41) showed a strong correlation between the percentage of the re-
leased drug and subharmonic acoustic emissions detected by fluorescence measurements.
Performed measurements indicated that the drug release is triggered by the cavitation,
which perturbs the structure of the micelle and releases the drug.
In the study of Liu et al. (49), it is shown that transient acoustic cavitation plays a
dominant role in drug release from micelle cores. In the experiments on the effect of ul-
trasound on the drug uptake from Pluronic solutions they observed a threshold of power
densities, below which no cell lysis occurred. However, sonication at power densities
above the threshold resulted in pronounced cell lysis. The existence of a threshold sug-
gested the important role of transient cavitation in the perturbation and damaging of the
cell membrane and in cell lysis. It was therefore proposed that, in addition to the releas-
ing mechanism, the violently collapsing bubbles or micelles are responsible for mechani-
cal rupturing of the cell membrane, hence inducing sonoporation and allowing entry of
molecules (drugs) into the cells (50).
Drug targeting by ultrasound requires the use of sharp ultrasound waves focused
on the tumor and does not require ultra-high ultrasound energies. Typically, the frequ-
encies of ultrasound used in studies of micellar-encapsulated drug delivery are in the
range of 20–90 kHz (41–45). It has been found that drug release was most efficient at ul-
trasonic frequency of 20 kHz and decreased with increasing frequency despite much
higher power densities (41). It has also been shown that at constant frequency drug re-
lease increases with increasing power density (41). Optimal power density of ultrasound
waves ranges from 1 to 5 W cm–2, depending on the time period of sonication, which is
typically 30 s up to a few minutes when continuous wave ultrasound is applied (41–45).
Higher ultrasound energies (5–15 kW cm–2) and longer treatment times (a few hours)
are used to directly kill the tumor cells by means of hyperthermia and tumor ablation. In
addition to the continuous wave ultrasound exposures, scientists are nowadays begin-
ning to use pulsed or high-frequency focused ultrasound. The effect of high-frequency
ultrasound on the drug release from Pluronic micelles and intracellular uptake by leuke-
mia HL-60 cells was studied by Marin et al. (44). The onset transient cavitation and drug
release from micelles were observed at much higher power densities than those mea-
sured at low-frequency ultrasound. Although several studies have shown the advan-
tages of pulsed high-intensity focused ultrasound exposures for enhancing the delivery
of micellar-encapsulted drugs, the work of Frenkal et al. (51) revealed that it was not the
case for drugs encapsulated in liposomes, probably because of their inherent ability to
preferentially accumulate into tumors on their own. Exposure of micellar-encapsulated
drugs to pulsed ultrasound waves showed that the drug uptake increases with increas-
ing pulse duration in the range of 0.1–2 s, and for pulses with longer duration the up-
take is close to that under exposure to continuous ultrasound waves (43).
The most widely used chemotherapeutic agent in the ultrasound-mediated drug de-
livery studies is doxorubicin (DOX). DOX is an intercalating drug that stacks between
paired bases in DNA. A strong drug-DNA interaction is critical for the cytotoxic effect.
However, like other anticancer drugs of anthracycline family, DOX is cardiotoxic due to
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the induced production of active oxygen radicals (52). In the last few years, numerous
studies of DOX delivery and action were performed in vitro on leukemia HL-60 cells,
ovarian carcinoma drug-sensitive and multidrug-resistant cells and breast cancer cells,
all of them showing enhanced DOX release from micelles and increased uptake of the
free and micellar-encapsulated DOX mediated by ultrasound (41–46).
The most detailed study of ultrasonic enhancement of the uptake of DOX by cancer-
ous cells from Pluronic micelles was performed by Marin et al. (43). They employed various
techniques, such as electron paramagnetic resonance spectroscopy, fluorescence micros-
copy and flow cytometry, in order to examine ultrasound-mediated enhancement of both
the intracellular uptake of Pluronic micelles and Pluronic trafficking into cell nuclei. A
model has been suggested that describes various equilibria controlling drug/cell inter-
actions and the effect of ultrasound on these equilibria. Under the action of ultrasound,
the equilibrium between the micellar-encapsulated and free drug is shifted in the direc-
tion of the free drug due to the micelle perturbation. The equilibrium between the extra-
cellular and internalized drug is shifted to the intracellular drug because of the ultrasound-
-induced cellular changes that enhance the accessibility of various cellular structures to
the drug. They also showed another important advantage of ultrasound – the same de-
gree of the intracellular drug uptake may be achieved at a substantially lower drug con-
centration in the incubation medium.
The significant success of in vitro studies of ultrasound-mediated drug delivery pro-
moted the experiments on laboratory animals and recently the first in vivo experiment
on colon cancer in rats was reported (53). In vivo results showed that application of low-
-frequency ultrasound (20–70 kHz) significantly reduced the tumor size compared to non-
-irradiated controls.
Except in cell cultures, there are very few studies of ultrasound-mediated drug de-
livery performed on animal models. The knowledge of the mechanism of sonoporation
is still very limited, which constitutes a major obstacle in determination of the factors af-
fecting acoustically triggered release and in the development of the standard protocols
for successful anticancer therapy. It is to be expected, however, that in the near future a
growing amount of experimental data would lead to extensive application of this stra-
tegy in various cancer models in vivo.
EPR experiments in ultrasound-mediated drug delivery and cell killing
Electron paramagnetic resonance (EPR) spectroscopy is a technique that allows de-
tection of molecules with an unpaired electron (radicals) by measuring the absorption of
high frequency microwave energy during the transition of the unpaired electron betwe-
en two spin levels, which have different energies when exposed to an external magnetic
field.
Unfortunately, in the majority of biological systems, radicals have a strong tendency
to pair the spin of the lone electron by reacting with another molecule or radical, which
results in a lifetime too short to build up sufficient steady-state concentrations that would
permit the EPR detection. One of the most useful techniques employed to overcome this
limitation is the spin trapping method. In this technique, the reactive radical adds to the
double bond of diamagnetic molecule (spin trap) forming a more stable covalent para-
magnetic adduct, which is EPR observable. The most frequently used are nitrone and
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nitroso spin traps with the unpaired electron located on oxygen atom (N-O  ), such as
N-tert-butyl-  -phenyl nitrone (PBN),  -(4-pyridyl-1-oxy)-N-tert-butylnitrone (POBN) or
5,5-dimethyl-1-pyrroline N-oxide (DMPO). Today, EPR spectroscopy is the most confi-
dent technique for both the direct detection and characterization of the free radicals al-
ready present in the system and for monitoring the actions of spin labeled particles added
in the system. There is a wide range of applications of this physical technique in biologi-
cal, biochemical and biophysical studies of the free radicals in biologically interesting
systems. Some of these applications include studies of free radicals formed in irradiated
model systems of DNA bases and their analogues (54, 55), studies of the complexation of
the DNA bases with metallic ions (56, 57) and studies of the complexation of the ions of
transition metals with biologically important molecules (58, 59).
In the experiments of ultrasound-mediated drug delivery, a very frequently used
drug is ruboxyl, a paramagnetic analogue of doxorubicin. Ruboxyl has a nitroxide part
in its structure and can thus serve as a spin trap, which can be easily monitored by EPR.
Ruboxyl molecule is also fluorescent (because of the anthracycline part), which makes it
a powerful tool for investigations of the drug uptake, distribution and metabolism. Us-
ing the EPR technique, Rapoport et al. (60) investigated the effect of the Pluronic micelle
structure and ultrasound on the uptake of ruboxyl and the distribution of ruboxyl mole-
cules in Pluronic micelles within various temperature regions. They observed two dis-
tinct EPR spectra of ruboxyl in Pluronic solutions with different values of characteristic
EPR parameters (hyperfine splittings), which indicated the existence of two drug popu-
lations differing in mobility and hydrophilicity of the nitroxide environment – one po-
pulation located outside the micelles and the other in the micelles’ core. From the fea-
tures of these two EPR spectra, they also concluded that 70% of ruboxyl molecules were
solubilized within Pluronic micelles at room temperature. In this manner, the EPR tech-
nique can be used for screening various members of the Pluronic family in order to de-
termine their micellization behavior. Moreover, the EPR technique can provide useful in-
formation on the structure of Pluronic micellar solutions, such as solubilization
efficiency, polarity and microviscosity of the solute environment, critical concentration
for the formation of micelles and micelle aggregation number (60).
Several studies have reported that products of ultrasonic cavitation are free radicals,
such as hydroxyl, singlet oxygen and hydroperoxyl, indicating that these molecules play
an important role in the synergism between ultrasound exposure and drugs (61). EPR
spin trapping technique has been used to study these reactive radical intermediates in a
promising new approach for cancer treatment termed sonodynamic therapy, which re-
fers to synergistic cell killing by both ultrasound and drugs. In several sonochemical
EPR studies, Mi{ik et al. (61, 62) showed that the cavitation-dependent sonodynamic ac-
tion of different classes of compounds is mediated by the formation of free radicals by
pyrolysis inside cavitation bubbles or by hydrogen abstraction by  OH radicals and  H
atoms from these compounds, followed by the formation of peroxyl radicals in the pre-
sence of oxygen. These radicals, by virtue of their lower reactivity and hence higher se-
lectivity, are capable of diffusing longer distances and damaging important cellular sites
more efficiently than the short living  H and  OH radicals.
The structure and reactivity of products emerging by interactions of naturally oc-
curring antioxidants (vitamins) with radical intermediates can be easily followed by EPR.
In order to determine which free radicals lead to an increase of drug content, effects of
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free radical scavengers (antioxidants) on increased intracellular adriamycin accumula-
tion mediated by ultrasound were investigated by Yu et al. (63). They showed that the
hydroxyl radical is the most important, because it leads to promotion of membrane per-
meability. Also, the study revealed that vitamin C and vitamin E are very effective in de-
creasing intracellular uptake of adriamycin, indicating that antioxidants effectively re-
duce cavitation by rapidly reacting with O2– radicals and thus protect cells from damage
induced by ultrasound exposure.
The measurement of sonoporation using the voltage clamp technique
Due to the lack of methods for real-time monitoring of sonoporation at the cellular
level, the efficiency of drug delivery and sonoporation-associated side effects, such as
loss of cell viability and enhanced apoptosis, have been studied only by post-ultrasound
exposure analyses. One of the techniques that allows real-time monitoring of the changes
in the cell membrane permeability is the voltage clamp technique. The voltage clamp is
a current generator with two electrodes. Transmembrane voltage is recorded through a
voltage electrode, relative to the ground, and a current electrode passes the current into
the cell. The electrodes are connected to an amplifier, which measures membrane poten-
tial (Vm) and also gets an input from the signal generator that determines the command
potential (Vc). The difference between the command potential and actual voltage of the
cell (Vc – Vm) is an output to the electrode current. Whenever the membrane potential
deviates from the command potential, the amplifier generates an error signal, and the
feedback circuit passes the current into the cell to reduce the error signal to zero. Thus,
the clamp circuit produces a current equal and opposite to the ionic current. This can be
measured, giving an accurate reproduction of the currents flowing across the membra-
ne. Detected changes in the transmembrane current amplitude directly reflect the chan-
ges in the cell membrane conductance and can therefore provide sensitive indications of
the formation and subsequent resealing of pores in the cell membrane.
To investigate the dynamics of sonoporation, Deng et al. (64) employed the two-
-electrode voltage clamp technique to obtain a real-time measurement of the transmem-
brane current of a single Xenopus oocyte during ultrasound irradiation in the presence of
albinum-shelled gas bubbles. During measurements, the membrane potential of the o-
ocyte was clamped at –50 mV by two microelectrodes inserted into its membrane. Ultra-
sound activation and duration were synchronized using trigger signals from the voltage
clamp for recording the transmembrane current and thus permitting capture of the cell
membrane status before, during and after ultrasound irradiation in real-time. The ob-
served characteristic stepwise transmembrane current changes during the voltage clamp
measurements are ascribed to an ultrasound-mediated pore formation (increasing of trans-
membrane current) and subsequent recovery of the cell membrane (decreasing of trans-
membrane current). They also showed that the inward transmembrane current increases
after a delay of ultrasound activation and that the current reaches a maximum value at
the end of ultrasound duration. For the ultrasound with the duration of 1 s and pressure
amplitude less than 1 MPa, the observed recovery time is in the order of 4 to 10 s. For
higher ultrasound pressures (greater than 1 MPa), they observed an irreversible current
increase, which indicates spontaneous cell death, confirmed also by an immediate mi-
croscopic examination.
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In a similar study using Xenopus oocyte as a model system, Zhou et al. (65) employed
the voltage technique to investigate the pore membrane formation, extension and reseal-
ing by measuring the transmembrane current as a direct result of decreased membrane
resistance due to the pore formation induced by ultrasound application. They observed
that the transmembrane current amplitude increases with increasing duration of the ap-
plied ultrasound waves, while the recovering mechanism of membrane pores and cell
survival rate decreases with longer duration.
These studies demonstrate that the novel application of electrophysiology methods,
such as the two-electrode voltage clamp techniques, allows to study the cell response to
ultrasound exposure in real-time. Monitoring and characterization of the dynamic cell
sonoporation process provides information essential for better understanding of the so-
noporation mechanism, which can then serve as a guidance for optimal design of ultra-
sound protocol applied in drug delivery to tumors.
APPLICATION OF MAGNETIC FIELDS IN DRUG DELIVERY TO TUMORS
Drug delivery by magnetoliposomes
Magnetoliposomes are liposomes with ferromagnetic particles embedded into their
lipid bilayer (66). Magnetic particles functionalized with the drug can serve as potential
drug carriers in a new drug delivery strategy based on the application of external mag-
netic fields. The principle of drug delivery by magnetoliposomes is based on the use of
both constant and high-frequency oscillating magnetic fields. A constant magnetic field
provides targeted drug delivery, while a high-frequency oscillating magnetic field is re-
sponsible for the controlled release of encapsulated drug. Since the magnetic particles in
magnetoliposomes are made of ferromagnetic materials (iron, cobalt, nickel as well as al-
loys containing these elements), they are attracted to high magnetic flux density and thus
can be targeted to specific areas (cancer tissues) by external constant magnetic fields. Re-
leasing mechanism is evoked by thermal excitations of these biocompatible magnetic
particles induced by an external high-oscillating magnetic field (67). Magnetic-field-in-
duced excitations produce heat that increases the temperature of magnetoliposomes. Such
specific heating represents a triggering mechanism for controlled release of conjugated
therapeutic compounds from magnetoliposomes when they are heated to sufficiently high
temperatures (around 40 °C) (68).
It has been shown that by using this kind of transport, the drug may be applied
very selectively at a particular site of the organism and this procedure may be repeated
several times using stealth magnetoliposomes, which are circulating in the blood-stream
for several days (69).
Moreover, magnetoliposomes concentrated by the external constant magnetic field
in tumor vasculature may lead to embolic lesions and necrosis of a tumor body. In addi-
tion, the heat produced for thermal activation of the drug enhances the effect of chemo-
therapy by means of local hyperthermia of tumor cells (see next chapter).
Zhang et al. (70) reported that lyophilized negatively charged magnetoliposomes could
be used as paclitaxel carriers in the treatment of breast carcinoma. Pharmacokinetic stu-
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dies showed that encapsulation of paclitaxel in magnetoliposomes produced a much
higher concentration of paclitaxel at the tumor site than the use of lyophilized conven-
tional liposomes.
Babincova et al. (71) developed magnetoliposomes encapsulated with doxorubicin
for site-specific anticancer therapy in response to an externally applied oscillating mag-
netic field. The results revealed that specifical heating of magnetoliposomes to 42 °C re-
sulted in a massive release of encapsulated doxorubicin.
Another in vivo study with doxorubicin showed that administration of magnetoli-
posomes under an applied external magnetic field produced an approximately four times
higher doxorubicin concentration in the tumor compared to the doxorubicin solution
applied (72). These results suggest that systemic chemotherapy could effectively control
the primary tumor without significant side effects due to the specific targeting of mag-
netic doxorubicin liposomes.
Kullberg et al. (73) used magnetoliposomes to target the epidermal growth factor
(EGF) receptors of the tumor cells. Combining the transport of toxins by magnetolipo-
somes with the increased level of specificity originating from additional EGF receptor
molecules, they showed that a tumor cell endosome has a 25 times greater chance to re-
ceive the toxin in comparison with normal cells.
All of these studies promote a new strategy for drug delivery to tumors based on
specifically developed drug carriers, consisting of magnetic particles that can be target-
ed by an external magnetic field. The application of external magnetic fields to these
functionalized magnetic particles with their unique features further improves the drug
delivery to tumor tissues and establishes a new anticancer treatment, generally based on
the physical principles of magnetism.
Magnetic fluid hyperthermia
Hyperthermia is the use of therapeutic heat to treat various cancers on and inside
the body. The purpose of this anticancer therapy is to shrink and hopefully destroy can-
cer without harming noncancerous cells. It can be used to treat cancer in many areas of
the body, including brain (74), thyroid (75), lungs (76), breast (77), and prostate (78). It is
thought that high temperatures, up to 40 °C, can help shrink cancerous tumors. Hyper-
thermia is now being used more widely, because it does not have as many negative side
effects as conventional forms of cancer treatment such as radiation or chemotherapy. In
some instances, hyperthermia is used in combination with other forms of cancer therapy
(79).
Hyperthermia can be used on very small areas of the body to the entire body itself.
Local hyperthermia refers to heating only one body area, usually where the tumor is lo-
cated. The heat can be applied using microwaves (80), high-frequency radio waves (81)
or magnetic fields (82). The heating mechanism achieved by the combined use of mag-
netic fields and specifically developed hyperthermia-causing anticancer agents will be
discussed in detail.
Magnetic fluid hyperthermia (MFH) is a novel anticancer therapy, based on the use
of magnetic fluids composed of ferromagnetic nanoparticles coated with biocompatible
materials (83). These magnetic particles can be targeted to specific areas of a human body
by focused external magnetic fields or by simple intratumoral injection (83).
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Since magnetic fluids have a specifically high absorption rate per mass, by the use
of external oscillating magnetic field, it is possible to selectively excite areas containing
fluids without interference with different neighboring tissues that normally have a lower
absorption rate (67). Such magnetic-field-induced excitation produces heat absorbed mostly
by magnetic fluids and thus increasing the temperature only in regions with accumu-
lated magnetic nanoparticles.
The main objectives in providing a successful MFH treatment are: (i) to create stable
magnetic fluids, (ii) to develop an apparatus that is capable of producing oscillating mag-
netic fields and heating the magnetic fluids, (iii) to determine the range of field strengths
and frequencies suitable for particular fluids used in MFH therapies, and (iv) to estimate
the specific absorption rate of magnetic fluids accumulated at tumor sites as well as the
number, size and position of magnetic nanoparticles depots required for sufficient heat
deposition. The results of electron microscopy, X-ray spectroscopy and calorimetric mea-
surements in several studies have confirmed that the use of magnetic fluids with strengths
between 4–12.5 kA m–1 and frequencies in the region 500–800 kHz (depending on the
used magnetic nanoparticles) is optimal for producing heating of magnetic fluids up to
42 °C, which is required for successful MFH treatments (83–86).
Nanoparticles found to be very promising for the use in magnetic fluids for MFH
treatments are superparamagnetic nanoparticles with the core consisting of iron oxides
that can be targeted through external magnetic fields (85). In several studies, the appli-
cation of Fe2O3 nanoparticles in MFH treatments has been investigated in vivo on pa-
tients with hepatocellular carcinoma (86, 87). The use of iron oxide particles inhibits pro-
liferation and induces apoptosis of SMMC-7731 tumor cells and thus has a significant
inhibitory effect on the mass and volume of treated cancer, superior to the effects pro-
duced by conventional anticancer therapies.
Johannsen et al. (83) evaluated the potential of MFH as a minimally invasive treat-
ment for prostate cancer by carrying out a systematic analysis of the effects of MFH in
the orthotopic Dunning tumor model of the rat. Rats received two MFH treatments fol-
lowing a single intratumoral injection of magnetic fluid. Treatments were carried out for
10 days after tumor induction using an oscillating magnetic field. The rats were sacri-
ficed after 20 days, and the tumor mass was determined and compared with the control.
The results indicated that the MFH treatment led to significant growth inhibition in the
orthotopic model of this tumor.
In another study, this group of authors reported on the evaluation of the effect of
MFH therapy combined with external radiation in the Dunning tumor model of prostate
cancer induced in rats (88). They showed an additive effect demonstrated for the com-
bined treatment at a radiation dose of 20 Gy, which was equally effective in inhibiting
tumor growth as 60 Gy radiation alone.
Recently, the same group of authors presented the first clinical application of inter-
stitial hyperthermia treatment using magnetic nanoparticles in locally recurrent human
prostate cancer (89). The study provided preliminary results necessary for the evalua-
tion of feasibility, toxicity and quality of life during MFH in patients with biopsy-proven
local recurrence of prostate cancer following radiotherapy.
Fortunately, the obtained data clearly indicated that the administration of biocom-
patible magnetic nanoparticles excited by oscillating external magnetic fields in the mag-
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netic fluid hyperthermia anticancer therapy is a promising new approach for anticancer
treatment. Also, there is no doubt that rapidly growing development of new drug car-
rier systems containing magnetic nanoparticles, along with the huge amount of new bio-
logical data on heat response of cells and tissues, will further improve this anticancer
treatment.
APPLICATION OF ELECTRIC FIELDS IN DRUG DELIVERY TO TUMORS
Electrochemotherapy
The combined treatment consisting of a chemotherapeutic agent and pulsed electric
fields has been termed electrochemotherapy (ECT). This relatively new treatment relies
on the physical effect of locally applied electric fields to destabilize cell membranes in
the presence of a drug. The destabilization of cell membranes has been described as a di-
electric breakdown due to an induced transmembrane potential that results from electri-
cal treatment (90). When the transmembrane voltage induced by the external electric field
exceeds a certain threshold (normally 0.2–1 V), a rearrangement of the molecular struc-
ture of the membrane occurs, leading to pore formation and a considerable increase in
the cell membrane permeability to ions, molecules and even macromolecules. This phys-
ical phenomenon was termed electroporation or electropermeabilization, because it was
observed that molecules that do not normally pass the membrane gain intracellular ac-
cess after the cells were treated with electric fields. In the case of small molecules, such
as anticancer drugs, transfer into the cell interior occurs through simple diffusion, and in
the case of macromolecules, such as DNA, transfer is accomplished by a multi-step me-
chanism that involves electrophoretically driven processes allowing passage of the mac-
romolecules through the destabilized membrane (91). Porous state of the cell membrane
was noted to be temporary. Typically, upon the application of electric pulses, cells re-
main in a destabilized state for several minutes.
In the ECT treatments, the electric-field-mediated permeabilized state of membran-
es is used to load tumor cells with anticancer drugs that do not easily enter the cells
through intact membranes (non-permeant drugs) (92) or partially enter the cells by dif-
fusion (low-permeant drugs) (93).
There are four parameters to be taken into account when administering the electric
component of ECT: electric field strength, pulse width (duration of the pulse), number of
pulses and duty cycle. The intensity of electrical treatments is described by the magni-
tude of the applied electric field. Electric field strengths ranging from 1100 to 5000 V cm–1
have been used for ECT and are also specific to the cells (tissues) under investigation.
Field strengths below 1250 V cm–1 were found to be less effective in most ECT treat-
ments (94). Fields between 1250 and 1500 V cm–1 gave similar results, providing excel-
lent delivery and marked antitumor effects (94). Pulses are usually rectangular in shape;
however, exponentially decaying pulses have also been used. ECT has been performed
with the pulse widths ranging from microseconds to milliseconds. The number of deli-
vered pulses can range from one to eight pulses per second. Typically, multiple pulses
are utilized during the ECT treatment, allowing the use of much lower doses of antican-
cer agents (up to 20-fold decrease) in ECT treatments that still yield results equivalent to
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a single treatment (95). Also, it was noted that the maximum antitumor effects were ob-
tained when pulses were administered between 8 and 28 min after injection of the anti-
cancer agents (96). This indicated the time when the drug concentrations were highest in
the interstitial fluid surrounding the tumor cells.
Thus far, only two drugs have been used in electrochemotherapy – non-permeant
bleomycin and low-permeant cisplatin. The anticancer effect of other currently used drugs
is not increased by the electric pulses because these drugs easily enter the cells by diffu-
sion or are actively pumped inside the cells (93). The drug most often used in ECT pro-
tocols and the only one used in clinical trials is bleomycin.
Bleomycin is a non-permeant hydrophilic drug and normally almost no bleomycin
molecules enter the intact cells. However, once inside the cell, bleomycin acts as an en-
zyme, creating single- and double-strand DNA-breaks and the uptake of 500 molecules
is sufficient to kill the cells (97). When the cells are electroporated, bleomycin at an exter-
nal concentration as low as 10–9 mol L–1 can enter the cells (91). Consequently, cytotoxi-
city of bleomycin can be augmented hundreds or thousands times by electroporation.
Jordan et al. (98) performed an experiment to enhance cell-killing effects of bleomy-
cin using electric field pulses with 50–200 kV cm–1 peak electric field strength, 150 ns
duration and nanosecond rise time. Dramatic increases in cell killing (approximately
factor 1000) were observed with a low dose of bleomycin after treatment with trains of
ten or more pulses at all electric field strengths tested, compared to pulse-only or drug-
-only treatments.
Byrne et al. (99) performed a study on nineteen patients with metastatic melanoma
to compare the anticancer activity using bleomycin together with ECT treatment with
bleomycin alone. Over a period longer than 12 weeks, they showed a 78% objective re-
sponse rate in the patients treated with bleomycin/ECT, which was significantly higher
than the 32% response rate observed in the patients treated with bleomycin alone.
Sersa et al. (100) reported that a metastasis of hypernephroma could be successfully
treated with ECT with bleomycin. ECT treatment resulted in stabilization of the tumor
volume for 12 months, whereas the subcutaneous metastasis next to the ECT-treated one
that did not receive electric pulses progressed immediately.
Applications of ECT with bleomycin are widely used nowadays. A large number of
animal models and recent clinical trials have been conducted for the treatment of vari-
ous types of tumors, such as head and neck squamos cell carcinoma, melanoma, hyper-
nephroma and basal cell carcinoma. Treatments of nonmetastatic cancers, such as basal
cell carcinoma, are ideal applications for ECT. The advantage of ECT in comparison with
other available therapies is the minimal scaring produced by a single treatment, for which
ECT can be used as a tissue sparing treatment. The use of ECT for extensive metastatic
diseases is not practical, except for palliative measures.
Recently, extensive research has been performed on the combined use of ultrasound
of various intensities (for both thermal effects and enhancement of drug delivery) with
permeabilizing effects of electric pulses on cell membranes. It was demonstrated in seve-
ral studies that tumor cells may be sensitized and subsequently destructed by this joint
treatment (101, 102). Obtained results suggest that the combined electric field and ultra-
sound therapy may provide a novel, drug-free modality for cancer treatment that might
have a great perspective in the near future.
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The latest modeling and experimental studies have shown that pulsed electric fields
of nanosecond duration (typically 10 ns) and megavolt per meter amplitude affect sub-
cellular structures, but do not lead to formation of large pores in the outer membrane
(103). Such short, highly powerful electric pulses can penetrate into the interior of tumor
cells and cause tumor cell nuclei to rapidly shrink and tumor blood flow to stop. Nuc-
citelli et al. (104) showed that this »intracellular electromanipulation« could shrink mela-
nomas by 90% within two weeks following a cumulative exposure to electric fields with
strengths greater than 20 kV cm–1 and 300 ns durations. This new therapy for treating
solid skin tumors provides a highly localized targeting of tumor cells with only minor
effects on the overlying skin. Typically, each pulse deposits energy of 0.2 J and 100 puls-
es increase the temperature of the treated region by only 3 °C, which is still lower than
the minimum temperature required for hyperthermia effects (104).
ECT is a noninvasive therapy for treatment of solid tumors that has proven its effi-
cacy in many different tumor types, both in preclinical and clinical trials. Investigations
of ECT in a multicenter study, called European Standard Operating Procedures for Elec-
trochemotherapy, demonstrate that over 80% of cutaneous and subcutaneous metastatic
nodules can be healed by ECT (105). Also, the physical nature of electroporation allows
the technique to be applied to any tissue. Therefore, a logical step forward for this drug
delivery method would be to adopt protocols for the treatment of internal tumors. This
includes treating nonresectable tumors and reducing large tumors during standard che-
motherapy treatments or prior to surgical excision. An additional investigation for trans-
lating ECT to internal tumors is currently in progress. All these facts, together with con-
tinuous development of appropriate equipment and efforts to prepare standard optimized
operating procedures, make the ECT a real alternative offered to treat solid tumors.
CONCLUSIONS
During the last 20 years, it was shown that there are unprecedented opportunities
to employ the mechanisms and principles of physics in order to gain more information
about the tumor cell behavior and to introduce and develop new mechanisms of drug
delivery and new carriers for anticancer agents. As described in this review, there are
plenty of possibilities of engaging the knowledge of physicists to acquire new insights
into the drug delivery to tumors and anticancer treatments. The proven efficacy of the
physical mechanisms for drug targeting and delivering to tumor cells, such as sonopo-
ration or electroporation, indicates that future success in developing new and improving
the existing effective anticancer therapies will require a coordinated, multidisciplinary
team approach, which must involve the knowledge of physicists.
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S A @ E T A K
Fizikalni mehanizmi i metode u prijenosu lijekova do tumora
ERIM BE[I]
Osim dobro poznatih metoda prijenosa lijekova u kemoterapijskom pristupu lije~e-
nja tumora, nedavno su otkriveni novi na~ini prijenosa koji se zasnivaju na specifi~nim
mehanizmima uzrokovanim upotrebom ultrazvuka, magnetskih i elektri~nih polja. U ~lan-
ku se daje prikaz fizikalnih mehanizama na kojima se temelje te nove metode, pregled
novootkrivenih prijenosnika lijekova (Pluronske micele, magnetoliposomi, magnetski flui-
di), novih na~ina terapije tumora (magnetska hipertermija, elektrokemoterapija) i najno-
vijih istra`ivanja temeljenih na fizikalnom pristupu ovoj problematici.
Klju~ne rije~i: prijenos lijekova, ultrazvuk, sonoporacija, EPR, magnetoliposomi, magnetska hiper-
termija, elektrokemoterapija, elektroporacija
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